60 Degrees Pharmaceuticals 公司计划就他非诺喹（Tafenoquine）用于治疗巴贝斯虫病（Babesiosis）的新药申请（NDA）路径，正式请求与美国食品药品监督管理局（FDA）举行会议。这一举措标志着该公司在推进该候选药物的监管进程中迈出了关键一步。
60 Degrees Pharmaceuticals 公司计划就他非诺喹（Tafenoquine）用于治疗巴贝斯虫病（Babesiosis）的新药申请（NDA）路径，正式请求与美国食品药品监督管理局（FDA）举行会议。这一举措标志着该公司在推进该候选药物的监管进程中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.